Wilson Disease

Genetics of Movement Disorders

Volumn , Issue , 2003, Pages 341-352

  Menkes, John H ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747774384     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012566652-7/50033-2     Document Type: Chapter

References (95)

1. Akil M., Brewer G.J. Psychiatric and behavioral abnormalities in Wilson's disease. Behavioral Neurology of Movement Disorders 1995, Vol. 65:171-178. Raven press, New York. W.J. Weiner, A.E. Lang (Eds.).
2. Andrews N.C. Mining copper transport genes. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:6543-6545.
3. Arima M., Takeshita K., Yoshino K., et al. Prognosis of Wilson's disease in childhood. Eur. J. Pediatr. 1977, 126:147-154.
4. Azizi E., Eshel G., Aladjem M. Hypercalciuria and nephrolithiasis as a presenting sign in Wilson disease. Euro. J. Pediatr. 1989, 148:548-549.
5. Bax R.T., Hässler A., Luck W., et al. Cerebral manifestation of Wilson's disease successfully treated with liver transplantation. Neurology 1998, 51:863-865.
6. Brewer G.J. Practical recommendations and new therapies for Wilson's disease. Drugs 1995, 50:240-249.
7. Brewer G.J. Wilson disease and canine copper toxicosis. Am. J. Clin. Nutr. 1998, 67(Suppl.):1087S-1090S.
8. Brewer G.J. Penicillamine should not be used as initial therapy in Wilson disease. Mov. Disord. 1999, 14:551-554.
9. Brewer G.J. Wilson's disease. Curr. Treat. Options Neurol. 2000, 2:193-204.
10. Brewer G.J., Dick R.D., Johnson V.D., et al. Treatment of Wilson's disease with zinc. XVI: treatment during the pediatric years. J. Lab. Clin. Med. 2001, 137:191-198.
11. Brewer G.J., Johnson V., Dick R.D., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 1996, 53:1017-1025.
12. Brewer G.J., Yusbasiyan-Gurkan V. Wilson disease. Medicine 1992, 71:139-164.
13. 52Fe-citrate PET study. J. Nucl. Med. 2000, 41:781-787.
14. Buiakova O.I., Xu J., Lutsenko S., et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum. Mol. Genet. 1999, 8:1665-1671.
15. Bull P.C., Thomas G.R., Rommens J.M., et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature. Genet. 1993, 5:327-337.
16. Butler P., McIntyre N., Mistry P.K. Molecular diagnosis of Wilson disease. Mol. Genet. Metab. 2001, 72:223-230.
17. Cairns J.E., Williams H.P., Walshe J.M. "Sunflower cataract" in Wilson's disease. Br. Med. J. 1969, 3:95-96.
18. Chowrimootoo G.F., Andoh J., Seymour C.A. Western blot analysis in patients with hypocaeruloplasminaemia. Q. J. Med. 1997, 90:197-202.
19. Chowrimootoo G.F., Scowcroft H., Seymour C.A. Caeruloplasmin isoforms in Wilson's disease in neonates. Arch. Dis. Child Fetal Neonatal Ed. 1998, 79:F198-F201.
20. Cox, D. W., (2002). Personal Communication.
21. Culotta V.C., Gitlin J.D. Disorders of copper transport. The Metabolic and Molecular Bases of Inherited Disease 2000, 3105-3126. McGraw-Hill, New York. 8th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Vogelstein, B. Chids (Eds.).
22. Curtis D., Durkie M., Balac (Morris) P., et al. A study of Wilson disease mutations in Britain. Hum. Mutat. 1999, 14:303-311.
23. Cuthbert J.A. Wilson's disease. Update of a systemic disorder with protean manifestations. Gastroenterol. Clin. North. Am. 1998, 27:655-681.
24. Dahlman T., Hartvig P., Lofholm M., et al. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). Q. J. Med. 1995, 88:609-616.
25. Duc H.H., Hefter H., Stremmel W., et al. His 1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. Eur. J. Hum. Genet. 1998, 6:616-623.
26. Ferlan-Marolt V., Stepec S. Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature. Dig. Dis. Sc 1999, 44:1054-1058.
27. Fleischer B. über einer der "Pseudosklerose" nahestehende bisher unbekannte Krankheit (gekennzeichnet durch Tremor, psychische Störugen, bräunliche Pigmentierung bestimmter Gewebe, insbesondere auch der Hornhautperipherie, Lebercirrhose. Deutsch. Z. Nervenheilk. 1912, 44:179-201.
28. Frazer D.M., Vulpe C.D., McKie A.T., et al. Cloning and gastrointestinal expression of rat hephaestin: relationship to other iron transport proteins. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281:G931-G939.
29. Frommer D.J. Defective biliary excretion of copper in Wilson's disease. Gut 1974, 15:125-129.
30. Gitlin J.D. Aceruloplasminemia. Pediatr. Res. 1998, 44:271-276.
31. Glazebrook A.J. Wilson's disease. Edinburgh Med. J. 1945, 52:83-87.
32. Godwin-Austin R.B., Robinson A., Evans K., Lascelles P.T. An unusual neurological disorder of copper metabolism clinically resembling Wilson's disease but biochemically a distinct entity. J. Neurol. Sci. 1978, 39:85-98.
33. Gow P.J., Smallwood R.A., Angus P.W., Smith A.L., Wall A.J., Sewell R.B. Diagnosis of Wilson's disease: an experience over three decades. Gut 2000, 46:415-419.
34. Grimm G., Oder W., Praye L., et al. Evoked potentials in assessment and follow-up of patients with Wilson's disease. Lancet 1990, 336:963-964.
35. Gu M., Cooper J.M., Butler P., et al. Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet 2000, 356:469-474.
36. Harada, M., Sakisaka, S., Kawaguchi, T. et al. Copper does not alter the intracellular distribution of ATP7 copper-transporting ATPase. Biochem. Biophys. Res. Commun.275, 871-876.
37. Harada M., Sakisaka S., Terada K., et al. A mutation of the Wilson disease protein. ATP7B, is degraded in the proteasomes and forms protein aggregates. Gastroenterology 2001, 120:967-974.
38. Hawkins R.A., Mazziotta J.C., Phelps M.E. Wilson's disease studied with FDG and positron emission tomography. Neurology 1987, 37:1707-1711.
39. Heann J., Saffer D. Abnormal copper metabolism: Another "non-Wilson's" case. Neurology 1988, 38:1493-1495.
40. Hoffman D.L., O'Halloran T.V. Function, structure, and mechanisms of intracellular copper trafficking proteins. Ann. Rev. Biochem. 2001, 70:677-701.
41. Huang I., Gitschier J. A novel gene involved in zinc transport is deficient in the lethal milk mouse. Nat. Genet. 1997, 17:292-297.
42. Lyengar V., Brewer G.J., Dick R.D., Chung O.Y. Studies of cholecytokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson's disease. J. Lab. Clin. Med. 1988, 111:267-274.
43. Jeon B., Kim J.M., Jeong J.M., et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J. Neurol. Neurosurg. Psychiatry 1998, 65:60-64.
44. Kayser B. Ueber einen Fall von angeborener grünlicher Verfärbung der Cornea. Klin. Monatsbl. Augenheilkd. 1902, 40:22-25.
45. King A.D., Walshe J.M., Kendall B.E., et al. Cranial MR imaging in Wilson's disease. Am. J. Roentgenol. 1996, 167:1579-1584.
46. Klein D., Lichtmannegger J., Heinzmann U., Summer K.H. Dissolution of copper-rich granules in hepatic lysosomes by penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats. J. Hepatol. 2000, 32:193-201.
47. Kontaxakis V., Stefanis C., Markidis M., et al. Neuroleptic malignant syndrome in a patient with Wilson's disease [Letter]. J. Neurol. Neurosurg. Psychiatry 1988, 51:1001-1002.
48. Lee J., Prohaska J.R., Thiele D.J. Essential role for mammalian copper transporter Ctrl in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6842-6847.
49. Lingan S., Wilson J., Nazer H., Mowat A.P. Neurological abnormalities in Wilson's disease are reversible. Neuropediatrics 1987, 18:11-12.
50. Loudianos G., Figus A.L., Loi A., et al. Improvement of prenatal diagnosis of Wilson disease using microsatellite markers. Prenatal Diagn. 1994, 14:999-1002.
51. Lüthy F. über die hepato-lentikuläre Degeneration (Wilson-Westphal-Strümpell). Deutsch. Z. Nervenheilk. 1931, 123:101-181.
52. Mason J., McQuaid A., Pheiffer H. Can patients with Wilson's disease be decoppered?. Lancet 1989, 1:1455.
53. McQuaid A., Mason J. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy. J. Inorg. Biochem. 1991, 41:87-92.
54. Menkes J.H. Menkes disease and Wilson disease: Two sides of the same copper coin. Part I. Menkes disease. Eur. J. Paed. Neurol. 1999, 3:147-158.
55. Mitchell A.M., Heller G.L. Changes in Kayser-Fleischer ring during treatment of hepatolenticular degeneration. Arch. Opthalmol. 1968, 80:622-631.
56. Miyajima H., Kono S., Takahashi Y., et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001, 57:2205-2210.
57. Mukhopadhyay C.K., Attich Z.K., Fox P.L. Role of ceruloplasmin in cellular iron uptake. Science 1998, 279:714-716.
58. Nanji M.S., Cox D.W. The copper chaperone Atox1 in canine copper toxicosis in Bedlington terriers. Genomics 1999, 62:108-112.
59. Oder W., Brucke T., Kollegger H., et al. Dopamine D2 receptor binding is reduced in Wilson's disease: A correlation of neurological deficits with striatal 123I-iodobenzamide binding. J. Neural. Transm. 1996, 103:1093-1103.
60. Ogihara H., Ogihara T., Miki M., et al. Plasma copper and antioxidant status in Wilson's disease. Pediatr. Res. 1995, 37:219-226.
61. Palsson R., Jonasson J.G., Kristjansoonk M., et al. Genotype-phenotype interactions in Wilson's disease: insights from an Icelandic mutation. Eur. J. Gasroenterol. Hepatol. 2001, 13:433-436.
62. Pandit A., Bhave S. Present interpretation of the role of copper in Indian childhood cirrhosis. Am. J. Clin. Nutr. 1996, 63:830S-835S.
63. Portala K., Westermark K., Ekselius L., von Knorring L. Personality traits in treated Wilson's disease determined by means of the Karolinska Scales of Personality (KSP). Eur. Psychiatry 2001, 16:362-371.
64. Prayer L., Wimberger D., Kramer J., et al. Cranial MRI in Wilson's disease. Neuroradiology 1990, 32:211-214.
65. Richter R. The pallial component in hepatolenticular degeneration. J. Neuropathol. Exp. Neurol. 1948, 7:1-18.
66. Rolfs A., Hediger M.A. Intestinal metal ion absorption: an update. Curr. Opin. Gastroenterol. 2001, 17:177-183.
67. Rumpel A. über das Wesen und die Bedeutung der Leberveränderungen und der Pigmentierungen bei den damit verbundenen Fällen von Pseudoskleroe, zugleich ein Beitrag zur Lehre der Pseudosklerose (Westphal-Strümpell). Deutsch. Z. Nervenheilk. 1973, 49:54-73.
68. Schaefer M., Hopkins R.G., Failla M.L., Gitlin J.D. Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver. Am. J. Physiol. 1999, 276:G639-G646.
69. Scheinberg I.H., Sterlieb I. Wilson's Disease 1984, W.B. Saunders, Philadelphia, PA.
70. Scheinberg I.H., Sternlieb I., Schilsky M., Stockert R.J. Penicillamine may detoxify copper in Wilson's disease. Lancet 1987, 2:95.
71. Schlaug G., Hefter H., Engelbrecht V., et al. Neurological impairment and recovery in Wilson's disease: evidence from PET and MRL. J. Neurol. Sci. 1996, 136:129-139.
72. Schumacher G., Platz K.P., Mueller A.R., et al. Liver transplantation: treatment of choice for hepatic and neurological manifestations of Wilson's disease. Clin. Transplant. 1997, 11:217-224.
73. Scott J., Golan J.L., Samourian S., Sherlock S. Wilson's disease presenting as chronic active hepatitis. Gastroenterology 1978, 74:645-651.
74. Shah A.B., Chernov I., Zhang H.T., et al. Identification and analysis of mutation in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype-correlation, and functional analyses. Am. J. Hum. Genet. 1997, 61:317-328.
75. Shiono Y., Hayashi H., Wakusawa S., Yano M. Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. Med. Electron. Microsc. 2001, 34:54-60.
76. Slovis T.L., Dubois R.S., Rodgerson D.O., Silverman A. The varied manifestations of Wilson's disease. J. Pediatr. 1971, 78:578-584.
77. Steindl P., Ferenci P., Dienes H.P., et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997, 113:212-218.
78. Strohmeyer F.W., Ishak K.G. Histology of the liver in Wilson's disease: a study of 34 cases. Am. J. Clin. Pathol. 1980, 73:12-24.
79. Sturniolo G.C., Mestriner C., Irato P., et al. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am. J. Gastroenterol. 1999, 94:334-338.
80. Theophilos M.B., Cox D.W., Mercer J.F.B. The toxic milk mouse is a murine model of Wilson disease. Hum. Molec. Genet. 1996, 5:1619-1624.
81. Thomas G.R., Forbes J.R., Roberts E.A., et al. The Wilson disease gene: spectrum of mutations and their consequence. Nat. Genet. 1995, 9:210-217.
82. Uzman L.L., Jakus M.A. The Kayser-Fleischer ring: A histochemical and electron microscope study. Neurology 1957, 7:341-355.
83. Van Wassenaer-van Hall H.N., van den Heuvel A.G., Algra A., et al. Wilson disease: findings at MR imaging and CT of the brain: clinical correlation. Radiology 1996, 198:531-536.
84. Voskoboinik I., Greenough M., La Fontaine S., et al. Functional studies on the Wilson copper P-type ATPase and toxic milk mouse mutant. Biochem. Biophys. Res. Commun. 2001, 281:966-970.
85. Vulpe C.D., Packman S. Cellular copper transport. Annu. Rev. Nutr. 1995, 15:293-322.
86. Vulpe C.D., Kuo Y.M., Murphy T.L., et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal transport, is defective in the sla mouse. Nature. Genet. 1999, 21:195-199.
87. Walshe J.M. Diagnosis and treatment of presymptomatic Wilson's disease. Lancet 1988, 2:435-437.
88. Walshe J.M. Penicillamine: the treatment of first choice for patients with Wilson's disease. Mov Disord. 1999, 14:545-550.
89. Walshe J.M., Dixon A.K. Dangers on non-compliance in Wilson's disease. Lancet 1986, 1:845-847.
90. Werlin S.L., Grand R.J., Perman J.A., Watkins J.B. Diagnostic dilemmas of Wilson's disease: Diagnosis and treatment. Pediatrics 1978, 62:47-51.
91. Wilson S.A.K. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain 1912, 34:295-509.
92. Wu J., Forbes J.R., Chen H.S., et al. The LEC rat has a deletion in the copper-transporting ATPase gene homologous to the Wilson disease gene. Nat. Genet. 1994, 7:541-545.
93. Wu J.C., Huang C.C., Jeng L.B., Chu N.S. Correlation of neurological manifestations and MR images in a patient with Wilson's disease after liver transplantation. Acta. Neurol. Scand. 2000, 102:135-139.
94. Yamaguchi Y., Aoki T., Arashima S., et al. Mass screening for Wilson's disease: results and recommendations. Pediatr. Int. 1999, 41:405-408.
95. Zhou B., Westaway S.K., Levinson B., et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Sptaz syndrome. Nat. Genet. 2001, 28:299-300.